Need Regulatory Help? Try Our Platform
Post your regulatory questions or request quotations from verified pharmaceutical consultants worldwide. Get matched with experts who specialize in your market.
January 17, 2026
Approximately 5 minutes
Indonesia Halal Law & MedTech: Risk-Based Timeline Guide for Chinese Consumable Manufacturers
Indonesia Halal Law & MedTech: Risk-Based Timeline Guide for Chinese Consumable Manufacturers
- Overview of Law No. 33 of 2014 Law No. 33 of 2014 on Halal Product Assurance (Undang-Undang Jaminan Produk Halal) establishes a mandatory halal certification system in Indonesia. It aims to guarantee that products consumed or used by the Muslim-majority population comply with Islamic law principles. The law covers food, beverages, medicines, cosmetics, and biological products, with gradual expansion to other categories including medical devices and consumables. Source: https://cmsbl.halal.go.id/uploads/Law_33_2014_on_Halal_Product_Assurance_8c328febdf.pdf The legislation creates a comprehensive framework managed by the Halal Product Assurance Organizing Agency (BPJPH) under the Ministry of Religious Affairs.
- Scope and Application to Medical Consumables Article 4 stipulates that products entering, circulating, or traded in Indonesia must be halal certified if they fall under regulated categories and contain or are derived from animal substances. For medical technology (MedTech), this applies selectively:
Consumables such as surgical gloves, syringes, wound dressings, IV sets, blood bags, and certain implants that include animal-derived components (e.g., gelatin, collagen, heparin) Products classified as “biological” or with potential for animal-derived materials Fully synthetic or metal-based devices without animal components are generally exempt from certification requirements Source: https://cmsbl.halal.go.id/uploads/Law_33_2014_on_Halal_Product_Assurance_8c328febdf.pdf
Non-consumable capital equipment (e.g., large diagnostic machines) is typically excluded unless it contains consumable components requiring halal certification. 3. Risk-Based Timeline and Key Milestones The law implements a phased enforcement schedule based on product risk classification (as amended and detailed in implementing regulations):
Class A (Low Risk): Mandatory by October 17, 2026 (e.g., simple bandages, gauze, manual wheelchairs) Class B (Medium-Low Risk): Mandatory by October 17, 2029 (e.g., syringes, surgical gloves, catheters) Class C (Medium-High Risk): Mandatory by October 17, 2034 (e.g., lung ventilators, orthopedic implants) Class D (High Risk): Mandatory by October 17, 2039 (e.g., heart valves, pacemakers) Source: https://cmsbl.halal.go.id/uploads/Law_33_2014_on_Halal_Product_Assurance_8c328febdf.pdf
For consumables, many fall into Class A or B, making 2026–2029 the critical compliance window. 4. Implications for Chinese Consumable Manufacturers Indonesia is a major export destination for Chinese medical consumables. The phased deadlines create targeted challenges:
Market Risk: Non-certified products with animal-derived components face import bans, product withdrawal, and penalties once enforcement hits Non-Halal Labelling: If a device contains non-halal materials (e.g., porcine-derived), it must be clearly labelled as “Non-Halal” with specific symbols/text—no outright ban but required disclosure Competitive Pressure: Manufacturers who certify early gain advantage in tenders and hospital procurement Source: https://cmsbl.halal.go.id/uploads/Law_33_2014_on_Halal_Product_Assurance_8c328febdf.pdf
Chinese companies exporting gloves, syringes, catheters, and similar items must assess animal content and prepare class-specific strategies. 5. Key Compliance Requirements To obtain halal certification under Law 33/2014 (for applicable products):
Submit application to BPJPH with product composition details Undergo halal audit of production processes (raw materials, manufacturing, storage) Ensure no haram (forbidden) substances or cross-contamination Obtain fatwa from the Indonesian Ulema Council (MUI) confirming halal status Affix halal label on packaging Source: https://cmsbl.halal.go.id/uploads/Law_33_2014_on_Halal_Product_Assurance_8c328febdf.pdf
For MedTech consumables, focus on tracing animal-derived materials and implementing segregation in supply chains. 6. Practical Survival Steps for 2026 and Beyond Chinese manufacturers should take these actions aligned with class timelines:
Conduct material audits to identify animal-derived components and classify products (A/B/C/D) Engage accredited halal certification bodies (LPPOM MUI or equivalent) for Class A by mid-2025 Implement halal assurance system (HAS) in factories, including supplier verification Prepare for on-site audits and process validations Coordinate with Indonesian importers/distributors for joint compliance and labelling Monitor BPJPH announcements for any extensions or clarifications Source: https://cmsbl.halal.go.id/uploads/Law_33_2014_on_Halal_Product_Assurance_8c328febdf.pdf
For exempt synthetic products, document proof of non-animal origin to avoid unnecessary certification. 7. Strategic Outlook While 2026 marks the start of full enforcement for Class A, the broader timeline (up to 2039 for Class D) provides phased preparation windows. Chinese manufacturers who proactively certify and adapt supply chains can turn compliance into a competitive edge in Southeast Asia’s largest market. Source: https://cmsbl.halal.go.id/uploads/Law_33_2014_on_Halal_Product_Assurance_8c328febdf.pdf Strategic alignment with the risk-based schedule is key to long-term market survival and growth in Indonesia.
Ask Anything
We'll follow up with you personally.
Related Articles
Approximately 5 minutes
How the 2026 Malaysia-China Reliance Program Accelerates IVD Registration
The Malaysia-China Medical Device Regulatory Reliance Programme Pilot Phase I (launched 30 July 2025) allows faster IVD registration in Malaysia by accepting NMPA approval decisions, reducing review time to approximately 30 working days for eligible Class B, C, and D IVDs while maintaining MDA oversight on local requirements.
Approximately 5 minutes
Vietnam Decree 98 Update: Why 2026 Becomes the Golden Year for Chinese Class B Medical Devices
Decree 98/2021/ND-CP, effective from 2022, introduced major simplifications for Class B medical devices. From 2026, Chinese manufacturers with NMPA approval can leverage streamlined registration without full local clinical trials or QMS audits in many cases, dramatically reducing time and cost for market entry in Vietnam.